Northern California Research is conducting a phase 3 clinical research study to evaluate the long-term safety and effectiveness of an experimental psoriasis medication (subcutaneous Mirikizumab – LY0374828) in patients with moderate to severe plaque psoriasis.
- Must have participated in the originating study and completed the final visit.
- Must be 18 years old or older.
- Women of childbearing potential must be willing to follow the birth control measures during and after study treatment.
Participants cannot have an unstable or uncontrolled illness that the study investigator thinks makes it unsafe or inappropriate to participate in the study. Participant must not have stopped taking mirikizumab during a previous study and may not participate if the study investigator does not think the participant should resume taking the study medication.
The trial doctor will review other eligibility criteria with you. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03556202